1. Introduction {#s0005}
===============

Cell-free DNA (cfDNA) refers to nucleic acids detected in body fluids and are thought to arise from two sources: passive release through cell death ([@bb0085]), and active release by cell secretion ([@bb0170]). DNA from cancer cells also contributes to the total load of cfDNA ([@bb0160]), and the fraction of cfDNA that comes from cancer cells is called circulating-tumor DNA (ctDNA). ctDNA has been estimated to make up about 0.01%--1% of cfDNA for early-stage disease, reaching over 40% for late-stage disease ([@bb0015], [@bb0025], [@bb0035], [@bb0045], [@bb0055], [@bb0125], [@bb0155]). Despite its intrinsic limitations, including technical issues in the sample collection, detection, and identification of tumor origin, ctDNA is emerging as a key potential biomarker for monitoring response to treatment and relapse ([@bb0040], [@bb0050], [@bb0055], [@bb0060], [@bb0120], [@bb0145], [@bb0165]). The potential of ctDNA is not limited to post-diagnosis surveillance but it may also play a crucial role in the detection of pre-clinical cancer. If successful, this could be translated into much improved cancer survival, in particular for those cancer sites that are typically diagnosed at a late stage, and for which survival is poor, such as lung, pancreatic, or esophageal cancer ([@bb0030]). However, implementation of ctDNA tests that detect pre-clinical disease in a non-symptomatic population will have to show an extremely high specificity if they are to provide meaningful results, or be part of a multi-modal screening program.

Very few studies have focused on the evaluation of ctDNA detection in early-stage cancers (*i.e.* stage I-II tumors) with even less data available on the detection of ctDNA in blood samples from pre-symptomatic cancer patients ([@bb0010], [@bb0015], [@bb0025], [@bb0060], [@bb0075], [@bb0095], [@bb0155]); Table S1). In addition, these studies have aimed to detect specific mutations in cfDNA (most of them using digital droplet PCR) following previous assessment of the tumor mutational profile. This approach is only viable for cancers with common hot-spot mutations and is not amenable for most screening purposes. This is because early detection of pre-clinical cancer requires variant detection to be done without prior knowledge from tumor tissue of the expected mutations. Another limitation of these studies is the major assumption that circulating-mutated fragments would be absent (or very rare) in individuals without cancer. Demonstrating that any ctDNA detection marker has a specificity close to 100% would be of fundamental importance for large-scale utility in an asymptomatic population ([@bb0180]).

Small-cell lung cancer (SCLC) accounts for about 15% of all lung tumors and has a 5-year survival below 5%. While SCLC tumors are initially sensitive to chemotherapy, they invariably relapse with a resistant and deadly disease. We and others have found that, contrary to lung adenocarcinomas and squamous-cell lung carcinomas, mutations in therapeutic targets are rare in SCLC ([@bb0070], [@bb0135], [@bb0150]). *TP53* is inactivated in virtually all SCLC cases, and *TP53* mutations are known to be an early event in the development of this disease. Given the almost uniform presence of *TP53* mutations in SCLC, we have investigated to what extent mutations in this gene can be identified in the cfDNA of patients with SCLC tumors. In addition, we have also assessed two independent series of non-cancer controls to evaluate the specificity of the approach.

2. Material and Methods {#s0010}
=======================

2.1. Study Population {#s0015}
---------------------

Small-cell lung cancer (SCLC) patients and controls were recruited through an IARC case-control study coordinated in Moscow from 2006 to 2012 ([@bb0190]). Cases were incident cancer patients collected from the Russian N.N. Blokhin Cancer Research Centre and the Moscow City Clinical Oncology Dispensary. The staging of the SCLC cases is based on the recent recommendations of the International Association for the Study of Lung Cancer (IASLC) ([@bb0130]). Controls were recruited from individuals visiting two Moscow general hospitals for disorders unrelated to lung cancer and its associated risk factors ([Table 1](#t0005){ref-type="table"}). The controls were matched for age, sex, and smoking status. All study participants provided written-informed consent and participated in an interview. Peripheral blood was collected in EDTA tubes at the time of interview and processed as rapidly as possible (generally within 2 h). For cases, blood draw was performed before surgery and any adjuvant treatment. Plasma samples were isolated by centrifugation of whole blood at 2000 ×* g* for 10 min at room temperature. Samples were stored at − 80 °C. All specimens were obtained in accordance with the declaration of Helsinki guidelines and were approved by the local Institutional Review Board and the IARC Ethics Committee. A total of 52 SCLC cases and 165 controls were initially included but only 51 SCLC and 123 controls passed the sequencing QC criteria (see [Sequencing Data Analyses, Annotation, and Filters](#s0040){ref-type="sec"}), and were therefore included in down-stream analyses.

In order to further evaluate the prevalence of circulating-mutated fragments in non-cancer controls, 114 additional controls were retrieved from two large multicenter case-control studies coordinated by IARC. One was a study on alcohol-related cancers and genetic susceptibility in Europe (the ARCAGE study) that was conducted from 2002 to 2005 and from which we included hospital-based controls recruited in Prague (Czech Republic), Athens (Greece), Aviano, Padova and Turin (Italy). The second was the Latin American study of head and neck cancer conducted from 1998 to 2002 and from which we selected hospital-based controls from two institutions in Buenos Aires (Argentina). Additional details of the 2 large multicenter case-control studies are included elsewhere ([@bb0105], [@bb0140]). Out of the 114 controls initially included, 102 passed the sequencing QC criteria (see [Sequencing Data Analyses, Annotation, and Filters](#s0040){ref-type="sec"}), and were therefore included in down-stream analyses.

2.2. cfDNA Extraction {#s0020}
---------------------

cfDNA was extracted from 0.8--1.3 mL of plasma using the QIAamp DNA Circulating Nucleic Acid kit (Qiagen) following manufacturer\'s instructions. cfDNA was eluted into 100 μL of elution buffer and quantified with the Qubit DNA high-sensitivity assay kit (Invitrogen Corporation). Details regarding amount of cfDNA are included in the Table S2.

2.3. Primer Design and Amplification of Targets {#s0025}
-----------------------------------------------

Twenty-one amplicons of 150 bp in size were designed (Eurofins Genomics Ebersberg, Germany) to cover exons 2 to 10 of *TP53*. The GeneRead DNAseq Panel PCR Kit V2 (Qiagen) was used for target enrichment. A validated in-house protocol was used to set up multiplex PCRs in 10 μL reaction volume, containing 5 ng cfDNA, 60 nM of primer pool and 0.73 μL of HotStarTaq enzyme. The experiments were carried out in two physically isolated laboratory spaces: one for sample preparation and another one for post-amplification steps. Amplification was carried out in a 96-well format plates DNA engine Tetrad 2 Peltier Thermal Cycler (BIORAD) as follows: 15 min at 95 °C and 30 cycles of 15 s at 95 °C and 2 min at 60 °C and 10 min at 72 °C.

2.4. Library Preparation and Sequencing {#s0030}
---------------------------------------

Following target enrichment, PCR products were purified using Serapure beads (prepared in-house and produced by ThermoFisher Scientific Inc.). A ratio of 2:1 of Serapure beads to PCR products was used. Purified amplicons were quantified with the Qubit DNA high-sensitivity assay kit (Invitrogen Corporation). Library preparation was done using 150 ng of purified PCR products and the NEBNext Fast DNA Library Prep Set for Ion Torrent (New England Biolabs, Ipswich, MA, USA) following manufacturer\'s instructions. Amplicons were end-repaired and ligated to the specific adapters and individual barcodes (designed in-house and produced by Eurofins MWG Operon, Ebersberg, Germany). Libraries were cleaned up, amplified with a final step of 6 PCR cycles, pooled in an equimolar way and loaded onto a 2% agarose gel and subjected to an electrophoresis at 150 V for 1.5 h. Fragments of 180--220 bp in size were selected and the pooled DNA library was recovered from the gel using the QIAquik Gel Extraction kit (Qiagen). The quality and quantity of the library was then assessed on the Agilent 2100 Bioanalyzer on-chip electrophoresis (Agilent Technologies, USA) for the absence of possible adapter dimers and heterodimers. The pooled libraries were sequenced on the Ion Torrent™ Proton Sequencer (Life Technologies Corp., USA) aiming for deep coverage (5,000 ×), using the Ion PI™ Hi-Q™ OT2 200 Kit and the Ion PI™ Hi-Q™ Sequencing 200 Kit with the Ion PI chip V3 (Life Technologies Corp., USA), following the manufacture\'s protocols.

2.5. Technical Duplication {#s0035}
--------------------------

Technical duplicates were undertaken for each sample including amplification, library preparation, and sequencing. Each technical duplicate pair was assessed on separate plates to limit the possibility of a contamination.

2.6. Sequencing Data Analyses, Annotation, and Filters {#s0040}
------------------------------------------------------

Short reads were aligned to the hg19 human reference genome and BAM files were generated using the Torrent Suite software (v4.4.2) with default parameters. Reads with a mapping quality below 20 were excluded from subsequent analysis. We also excluded those libraries for which the on-target median coverage was significantly lower in comparison to the other libraries sequenced in the same batch. On-target median coverage for both libraries is shown in Table S2.

For the calling of variants we used *Needlestack*, a recently developed ultra-sensitive variant caller, which estimates the distribution of sequencing errors across multiple samples to reliably identify variants present in very low proportion (<https://github.com/IARCbioinfo/needlestack>) (unpublished data; Delhomme et al.). Contrary to most existing algorithms, *Needlestack* can deal with both single nucleotide substitutions (SNVs) and short indels. At each position and for each candidate variant, sequencing errors are modeled using a robust negative binomial regression ([@bb0005]), with a linear link and a zero intercept. True variants are outliers from this error model ([Fig. 1](#f0005){ref-type="fig"}a). The robust estimator of the over-dispersion parameter avoids bias due to these outliers ([@bb0005]). For each sample a *p*-value against the null hypothesis of being a sequencing error is calculated, and further transformed into a *q*-value using the Benjamini and Hochberg false-discovery rate control method ([@bb0020]). *Q*-values are reported as a Phred-scale quality score: Q = − 10 log~10~(*q*-value), and we used a threshold of Q \> 50 to call variants. For each variant, we also calculated the relative variant strand bias defined by:$$\mathit{RVSB} = \frac{\max\left( {{\mathit{AO}_{p}\mathit{DP}_{m}},{\mathit{AO}_{m}\mathit{DP}_{p}}} \right)}{\mathit{AO}_{p}\mathit{DP}_{m} + \mathit{AO}_{m}\mathit{DP}_{p.}}$$where *DP* and *AO* denote respectively the total number of reads and the number of reads matching the candidate variant, with the subscripts *p* and *m* referring to the forward and reverse strands respectively. In the complete absence of strand bias, *RVSB* = 0.5 and *AO*~*p*~/*AO*~*m*~ = *DP*~*p*~/*DP*~*m*~, whereas for a completely biased variant, *RVSB* = 1. We filtered out variants with *RVSB* \> 0.85.

Variant calls were annotated using ANNOVAR ([@bb0200]). We only considered meaningful *TP53* mutations those that matched the following criteria: the mutation has already been reported in COSMIC and the mutation is a nonsense, indel, splicing or a missense variant that is classified as deleterious by SIFT or Polyphen.

2.7. Analyses of Technical Duplicates {#s0045}
-------------------------------------

While Needlestack models recurring errors, rare errors such as those generated by the DNA polymerase will be identified as variants. Such errors will be generally specific to a particular preparation. To filter out these rare errors, we required each of the individual\'s technical duplicate to be a Needlestack outlier ([Fig. 1](#f0005){ref-type="fig"}a). Additionally, we identified and excluded a few genomic positions that show a particularly high proportion (\> 10%) of these errors (*i.e.* higher than the estimated sequencing error rate, but not always replicable in two independent preparations).

2.8. Statistical Analyses {#s0050}
-------------------------

Effect of age, smoking, and alcohol status on the presence of *TP53* mutations was assessed using logistic regression adjusting one for the others. Effect of case-status on the presence of *TP53* mutations was assessed using unadjusted logistic regression. *p*-Values to test the differences between the pattern of mutations in cases and controls are derived from Pearson\'s chi-square tests. All the analyses were conducted using SAS 9.4. For comparison of allelic fractions, we log-transformed the data and performed a *t*-test (2 tailed, unequal variance).

3. Results {#s0055}
==========

The characteristics of the cases and controls are shown in [Table 1](#t0005){ref-type="table"}. We detected 31 *TP53* mutations in 25 SCLC patients (49%, 25/51). When the 51 initial SCLC cases were stratified by stage, we found that 35.7% (5/14) of the stage I--II and 54.1% (20/37) of the stage III--IV, carried detectable *TP53* mutations in their cfDNA ([Fig. 1](#f0005){ref-type="fig"}b). While statistically significant in cases *versus* controls (*p*-value = 6 × 10^− 9^), 18 *TP53* mutations were detected in 14 of the Russian non-cancer controls (11.4%, 14/123). The significance was also maintained when stratifying by stage (stage I--II *versus* controls, *p*-value = 0.012; stage III--IV *versus* controls, *p*-value = 1 × 10^− 8^). We replicated these observations in an independent series of 102 controls, and found a comparable proportion of *TP53* mutated samples (10.8%, 13 *TP53* mutations in 11 controls).

Similarly to what is expected for *TP53* mutations present in cancer, most of the mutations in cases and controls altered amino acids coding for the *TP53* DNA-binding domain, which is critical for the transactivation activity of this gene ([Fig. 1](#f0005){ref-type="fig"}c). We next evaluated the characteristics of the mutations found in cases *versus* controls. Chi-square test analysis showed that there was a statistically significant difference between the mutational pattern found in cases *versus* controls (*p*-value = 0.008). The fraction of nonsense, indel, or splicing mutations found in the cases was similar to that previously reported for SCLC tumors ([@bb0070]) (35.5% *versus* 37% respectively), whereas this proportion was slightly lower in controls (22.2% in the Russian, and 7.7% in the replication controls; [Fig. 1](#f0005){ref-type="fig"}d). We used the IARC *TP53* database to classify the missense mutations in functional, partially functional, or non-functional based on the *in vitro* transcriptional activity of the resulting protein. Most missense mutations found in SCLC tumors ([@bb0070]) (92.6%) and cfDNA from cases (100%) were classified as resulting in a non-functional protein. However, controls had a higher proportion of missense mutations that retained some transcriptional activity (\~ 30%; [Fig. 1](#f0005){ref-type="fig"}d).

We also compared the allelic fractions (AFs) of the *TP53* mutations found in the cfDNA of cases and controls. The AFs for a given mutation were similar in the two independent libraries, demonstrating the reproducibility of the assay (Table S3, S4, and S5). The AFs for the cases ranged from 0.12% to 84.81% (median 4.6%). In the Russian controls the AFs ranged from 0.19% to 84.94% (median 1.2%), and in the replication controls they ranged from 0.02% to 63.74% (median 0.5%) ([Fig. 1](#f0005){ref-type="fig"}e). The statistically significant difference in the AFs between cases and controls (*p*-value = 4 × 10^− 4^) is explained by the presence of late-stage SCLC tumors, since the median AF of the *TP53* mutations detected in the five stage I--II SCLC (0.9%) is not statistically different from that found in controls (*p*-value = 0.64), while it differed from the median AF of stage III-IV SCLC tumors (8.2%; *p*-value = 2 × 10^− 6^; [Fig. 1](#f0005){ref-type="fig"}e).

Finally, we sequenced the DNA extracted from the white-blood cells (WBC) of 39 cfDNA *TP53*-positive patients, from which material was available (19 cases and 20 controls). Five cfDNA *TP53* mutations (from one case and four controls) were detected in the WBC DNA, with similar AFs to those found in the cfDNA ([Table 2](#t0010){ref-type="table"}). For one control (MLT-14), the AFs in both cfDNA and WBC DNA were around 50%, being consistent with a heterozygous germ-line variant. The other four mutations were detected at AFs consistent with a somatic origin (AFs below 11%) in both cfDNA and WBC DNA (Table S2).

Taken altogether, cancer-like *TP53* mutations were identified in 25 of the 225 non-cancer controls analyzed in this study (11.1%). We checked if the presence of *TP53* mutations in the controls was correlated with age, smoking status, or alcohol (adjusting one for the other), but none of these factors was found to be associated.

4. Discussion {#s0060}
=============

Inactivation of *TP53* by mutation has been reported to occur in over 90% of SCLC cases ([@bb0070]). In this study we were able to detect *TP53* mutations in the cfDNA of 49% SCLC patients and, when stratifying by stage, in the cfDNA of 35.7% early-stage cases. These proportions matched those reported for other cancer types ([@bb0025]). Unfortunately, we did not have the correspondent tumors to confirm that the *TP53* mutations detected in the cfDNA originate from the SCLC tumors. However, our method detected *TP53* mutations in 60% of the cfDNA samples of an independent French series of 10 SCLC patients (all of them carrying *TP53* somatic mutations in their tumors). Importantly, each of the *TP53* mutations found in the cfDNA matched the one found in the SCLC tumor (data not shown).

We also observed cfDNA *TP53*-mutated fragments in 11.4% of 123 matched non-cancer controls. Acknowledging the potential for bias in our selection of controls (such as differential performance in QC criteria or cfDNA amount, between cases and controls), we screened a second series of 102 non-cancer controls, and found a comparable proportion of *TP53* mutated samples in this independent group (13 *TP53* mutations in 11 controls, 10.8%). Altogether, the detection of *TP53* mutations in 11.1% of the 225 non-cancer controls, from two independent groups of samples, suggests that the presence of circulating-mutated fragments among individuals without any diagnosed cancer is a common occurrence, and poses serious challenges for the development of ctDNA screening tests for the early detection of cancer.

Only two other studies have explored the potential presence of circulating-mutated fragments in non-cancer subjects. A study within the EPIC prospective cohort (GENAIR) that used blood samples from controls, found that *KRAS* and *TP53* mutations were detectable in the cfDNA of 1% and 3.2% healthy subjects, respectively, without a cancer diagnoses five years subsequent to blood draw ([@bb0075]). The higher percentage of *TP53*-positive controls in our analyses is likely to be explained by the fact that these analyses within EPIC were undertaken using DHPLC (denaturing high-pressure liquid chromatography) and Sanger sequencing, and these techniques are less sensitive and only allow for detection of mutations with allelic fractions of 3% or more. Further, only *TP53* exons five to nine were analyzed. If we limited our analysis to mutations from exons five to nine and AFs greater that 3%, we would have found a comparable number of *TP53*-positive controls (2.7%, 6/225). More recently, Krimmel and colleagues have reported extremely low-frequency cancer-like *TP53* mutations in the peritoneal fluid from both women with ovarian cancer and those with benign lesions, using duplex sequencing ([@bb0100]). They also showed that low frequency *TP53* mutagenesis increases with age and cancer. Overall, these results support the need for further ctDNA studies to incorporate series of non-cancer controls in order to improve validation of detection and analysis techniques.

A potential limitation of our study was the use of hospital controls as proxies of healthy people. Controls were admitted for a wide variety of routine conditions unrelated to tobacco and it is implausible that a high proportion of the controls with a detectable damaging *TP53* mutation developed a cancer in the short term. However, we cannot exclude this occurring in a small number of controls nor enriching for non-cancer diseases with unknown impact on the presence of circulating-tumor fragments. Nevertheless, as noted above, the prevalence of *TP53* mutations in our study is approximately equal to that of GENAIR (when applying the same detection thresholds). Prospective cohorts may help to overcome the limitations of using hospital controls and also help to determine at what point in the development of the disease is ctDNA detectable in blood, and its correlation with a plausible diagnosis.

The source of circulating-mutated fragments in the cfDNA of apparently healthy people is still unknown. There is, however, accumulating evidence that clonal expansions are more frequent than originally thought. Martincorena and colleagues estimated that there are 9.5 clones per cm^2^ of normal human skin carrying a driver mutation in *TP53* in a selected population for high-sun exposure ([@bb0115]). Such clonal expansions might act as a reservoir of circulating-mutated fragments in cfDNA. In addition, several studies have shown that a subset of normal individuals could undergo clonal hematopoiesis with mutations in driver genes ([@bb0065], [@bb0080], [@bb0090], [@bb0110], [@bb0185], [@bb0195]). Consistent with this, we observed 4 cfDNA *TP53* mutations that appeared to be from clonal expansions in WBC. We also noted 2 *TP53* mutations in one SCLC case, apparently from different organs; one originating from WBC, the second we assume from the SCLC tumor. Such ambiguity around the tissue of origin of the circulating-mutated fragments adds another layer of complexity when using ctDNA for early detection.

The potential of ctDNA for early diagnosis of cancer is an area of much interest ([@bb0175]). While implementation in a screening setting will undoubtedly require more sensitive and specific tests as well as validation in pre-diagnostic blood samples, the unexpected presence of known cancer mutations in cfDNA among non-cancer controls represents an important challenge.
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![Characteristics of *TP53* mutations in cases and controls\
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###### 

Characteristics of small-cell lung cancer cases and controls from Russia, and additional replication controls from Greece, Czech Republic, Italy, and Argentina.

Table 1

                                                                         Cases        Controls      Replication controls
  ---------------------------------------------------------------------- ------------ ------------- ----------------------
  Origin (country)                                                                                  
  Russia                                                                 51           123           
  Greece                                                                                            9 (8.8%)
  Czech Republic                                                                                    14 (13.7%)
  Italy                                                                                             40 (39.2%)
  Argentina                                                                                         39 (38.2%)
  Total                                                                  51           123           102
                                                                                                    
  Age at diagnosis                                                                                  
  \< 40                                                                  2 (3.9%)     2 (1.6%)      3 (2.9%)
  40--49                                                                 4 (7.8%)     11 (8.9%)     15 (14.7%)
  50--59                                                                 15 (29.4%)   42 (34.2%)    33 (32.4%)
  60--69                                                                 22 (43.1%)   55 (44.7%)    33 (32.4%)
  70 +                                                                   8 (15.7%)    13 (10.6%)    18 (17.7%)
                                                                                                    
  Sex                                                                                               
  Male                                                                   43 (84.3%)   107 (87.0%)   76 (74.5%)
  Female                                                                 8 (15.7%)    16 (13.0%)    26 (25.5%)
                                                                                                    
  Smoking status                                                                                    
  Never                                                                  5 (9.8%)     35 (28.4%)    34 (33.4%)
  Former                                                                 6 (11.8%)    28 (22.8%)    25 (24.5%)
  Current                                                                40 (78.4%)   60 (48.8%)    43 (42.1%)
                                                                                                    
  Alcohol status                                                                                    
  Never                                                                  30 (58.8%)   32 (26.0%)    16 (15.7%)
  Former                                                                 4 (7.8%)     18 (14.6%)    14 (13.7%)
  Current                                                                17 (33.4%)   73 (59.4%)    72 (70.6%)
                                                                                                    
  Tumor stage of cases                                                                              
  I                                                                      7 (13.7%)                  
  II                                                                     7 (13.7%)                  
  III                                                                    28 (54.9%)                 
  IV                                                                     9 (17.6%)                  
                                                                                                    
  Disease type of hospital controls                                                                 
  Infectious & parasitic diseases                                                     0 (0.0%)      1 (1.0%)
  Neoplasms                                                                           3 (2.4%)      0 (0.0%)
  Endocrine, nutritional and metabolic diseases and immunity disorders                6 (4.9%)      1 (1.0%)
  Diseases of blood and blood-forming organs                                          2 (1.6%)      1 (1.0%)
  Diseases of the nervous system and sense organs                                     28 (22.8%)    6 (5.9%)
  Diseases of the sense organs                                                        0 (0.0%)      5 (4.9%)
  Diseases of the circulatory system                                                  25 (20.3%)    2 (2.0%)
  Diseases of the respiratory system                                                  3 (2.4%)      3 (2.9%)
  Diseases of the digestive system                                                    19 (15.4%)    19 (18.6%)
  Diseases of the genitourinary system                                                19 (15.4%)    17 (16.7%)
  Diseases of the skin and subcutaneous tissue                                        3 (2.4%)      2 (2.0%)
  Diseases of the musculoskeletal system and connective tissue                        9 (7.3%)      18 (17.6%)
  Symptoms, signs and ill-defined conditions                                          0 (0.0%)      8 (7.8%)
  Injury and poisoning                                                                6 (4.9%)      18 (17.6%)
  External causes                                                                     0 (0.0%)      1 (1.0%)

###### 

Overview of the cfDNA mutations also detected in the white-blood cells (WBC) DNA, and their corresponding allelic fractions in each technical duplicate (AFs in %).

Table 2

  Sample    *TP53* mutation   AFs detected in cfDNA   AFs detected in WBC           
  --------- ----------------- ----------------------- --------------------- ------- -------
  SCLC-21   p.Y220C           0.90                    1.27                  0.50    0.70
  MLT-6     p.R175G           4.09                    4.41                  4.40    4.50
  MLT-14    p.G154S           47.17                   50.58                 52.10   54.90
  ARG-1     p.R273C           5.22                    5.58                  7.30    10.40
  ITA-8     p.V272M           0.78                    0.80                  0.90    1.40

[^1]: Equally contributing authors.
